Cambridge Nutritional Sciences Posts Robust FY25 Results and Eyes Continued Growth

Cambridge Nutritional Sciences plc (LSE:CNS) reported a solid financial performance for the fiscal year ending March 31, 2025, with total income rising 12% year-over-year to approximately £11.1 million. This growth was supported by a favorable settlement with the UK Department of Health and Social Care (DHSC), which further strengthened the company’s balance sheet.

The company posted a gross profit margin of about 65%, and an adjusted EBITDA of £0.4 million—demonstrating efficient cost management and underlying profitability. With the resolution of a long-standing legal matter now behind it, CNS is focused on capitalizing on an expanding revenue pipeline and executing on strategic investments in manufacturing and commercial operations.

Looking ahead, the company anticipates continued momentum into FY26, driven by strong distributor partnerships and growing demand across its core markets.

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences is a UK-based medical diagnostics company specializing in functional and personalized health testing. The company offers innovative solutions focused on nutrition and wellness, targeting consumers and healthcare providers in key markets including the UK, Europe, the US, and India. CNS is actively building international distribution channels to extend its reach in the growing health diagnostics sector.

• Average Daily Trading Volume: 167,643

• Technical Sentiment: Sell

• Market Capitalization: £6.78 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Neto Trade Analysis Department

• 

  Fiona Craig

• 

  Jagdip Cheema

• 

  Matt Simpson